{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Verastem, Inc."},"Symbol":{"label":"Symbol","value":"VSTM"},"Address":{"label":"Address","value":"117 KENDRICK STREET,SUITE 500, NEEDHAM, Massachusetts, 02494, United States"},"Phone":{"label":"Phone","value":"+1 781 292-4200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers."},"CompanyUrl":{"label":"Company Url","value":"https://www.verastem.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Daniel W. Paterson","title":"President, Chief Executive Officer & Director"},{"name":"John Hayslip","title":"Chief Medical Officer"},{"name":"Jonathan Pachter","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}